Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently Amended) A conjugate ~~for use in a liposomal drug delivery vehicle, the conjugate~~ having the general structural formula:



wherein L is a ~~hydrophobic moiety suitable for incorporation into a liposomal lipid bilayer~~phospholipid, R^1 represents a therapeutic drug covalently attached to the dithiobenzyl moiety, and where orientation of the CH_2R^1 group is selected from the ortho position and the para position.

2. (Original) The conjugate of claim 1, wherein the therapeutic drug is covalently attached by a linkage selected from the group consisting of urethane, amine, amide, carbonate, thio-carbonate, ether and ester.

3-6. Cancelled

7. (Original) The conjugate of claim 1, wherein said drug is selected from the group consisting of mitomycin C, mitomycin A, bleomycin, doxorubicin, daunorubicin, fluorodeoxyuridine, iododeoxyuridine, etoposide, AZT, acyclovir, vidarabine, arabinosyl cytosine, pentostatin, quinidine, atropine, chlorambucil, methotrexate, mitoxantrone and 5-fluorouracil.

8. (Original) The conjugate of claim 1, wherein the therapeutic drug is covalently linked to the dithiobenzyl moiety to form a conjugate having the structure:



wherein R^4 represents a residue of the therapeutic drug.

9. (Original) The conjugate of claim 8, wherein R^4 is a therapeutic drug residue containing a primary or a secondary amine moiety thereby forming a urethane linkage between the dithiobenzyl and the therapeutic drug.

10. (Original) The conjugate of claim 9, wherein said therapeutic drug is selected from the group consisting of mitomycin A, mitomycin C, bleomycin and a polypeptide.

11. (Original) The conjugate of claim 8, wherein R^4 is a residue of a carboxyl-containing therapeutic drug, thereby to form an ester linkage between the dithiobenzyl and the therapeutic drug.

12. (Original) The conjugate of claim 11, wherein said drug is chlorambucil or methotrexate.

13-14. Cancelled

15. (Currently Amended) A liposome composition, comprising

liposomes comprised of vesicle-forming lipids including from about 1 to about 30 mole percent of a conjugate <u>according to claim 1</u>~~having the general structural formula:~~



~~wherein L is a hydrophobic moiety suitable for incorporation into a liposomal lipid bilayer, R^1 represents a therapeutic drug covalently attached to the dithiobenzyl~~

~~moiety, and where orientation of the CH_2R^1 group is selected from the ortho position and the para position,~~

~~wherein said therapeutic drug is released from the conjugate *in vivo* in response to a physiologic condition or an artificially induced condition~~.

16-42. Cancelled